PreMD Inc.

PreMD, Inc., a predictive medicine company, develops non-invasive tests for the early detection of cardiovascular disease and cancer. It is developing tests designed for use at the point of care, in the doctor’s office, at the pharmacy, and at home. The company’s coronary artery disease risk assessment technology products include PREVU* Point of Care Skin Cholesterol Test that provides information about an individual’s risk of coronary artery disease, which obtained FDA clearance for commercial sale; PREVU* LT Skin Cholesterol Test, a lab-processed skin cholesterol test; and PREVU* PT Skin Cholesterol Test, a semi-quantitative consumer test that is under prototype development for home use. Its cancer tests under development include ColorectAlert and Coolpath mucus tests for the detection of colorectal cancer; LungAlert, a sputum test for the detection of lung cancer; and a nipple aspirate test for the detection of breast cancer. It has a license agreement with AstraZeneca Pharmaceuticals LP to market and distribute its skin cholesterol test in the United States. The company, formerly known as IMI International Medical Innovations, Inc., was founded in 1992 and is headquartered in Toronto, Canada.